NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Hoffmann-La Roche
AstraZeneca
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, San Diego
AstraZeneca
National Cancer Institute (NCI)
AstraZeneca
National Institutes of Health Clinical Center (CC)
Revolution Medicines, Inc.
National Cancer Institute (NCI)